Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01722669 · ClinicalTrials.gov registry record · Early Phase 1
Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States
A Early Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 38
- Enrollment target
NCT01722669 is a Early Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 38 participants.
The verdict
NCT01722669, a Early Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid antibodies
Interventions
- DRUG isoquercetin or quercetin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2012-05 |
| Est. Completion | 2019-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01722669
The ClinicalTrials.gov registry entry for NCT01722669 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which isoquercetin or quercetin is the first listed.
NCT01722669 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01722669 about?
NCT01722669 is a clinical study titled "Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States". The goal of this study is to evaluate how much quercetin or isoquercetin is absorbed after a single dose and evaluate for pharmacokinetic inhibition of protein disulfide isomerase. Pharmacodynamic studies will also be performed in an additional cohort of 10 patients with evidence of antiphospholipid...
What is the current status of trial NCT01722669?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 38 participants. The study started on 2012-05. Estimated completion is 2019-12.
What interventions are being tested in trial NCT01722669?
The interventions under investigation include: isoquercetin or quercetin (DRUG).
Who is sponsoring clinical trial NCT01722669?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.